**Exhibit 10.**3

Knightscope, Inc.

2022 Equity Incentive Plan

Stock Option Award Notice

[Name of Optionee]

You have been awarded a stock option to purchase shares of Class A Common Stock of Knightscope, Inc., a Delaware corporation (the “Company”), pursuant to the terms and conditions of the Knightscope, Inc. 2022 Equity Incentive Plan (the “Plan”) and the Stock Option Agreement (together with this Award Notice, the “Agreement”). The Stock Option Agreement is attached hereto. Capitalized terms not defined herein shall have the meanings specified in the Plan or the Agreement.

…

Knightscope, Inc.

2022 Equity Incentive Plan

Stock Option Award Notice

[Name of Optionee]

You have been awarded a stock option to purchase shares of Class A Common Stock of Knightscope, Inc., a Delaware corporation (the “Company”), pursuant to the terms and conditions of the Knightscope, Inc. 2022 Equity Incentive Plan (the “Plan”) and the Stock Option Agreement (together with this Award Notice, the “Agreement”). The Stock Option Agreement is attached hereto. Capitalized terms not defined herein shall have the meanings specified in the Plan or the Agreement.

…

STAAR SURGICAL COMPANY

AMENDED AND RESTATED OMNIBUS EQUITY INCENTIVE PLAN

STOCK OPTION GRANT NOTICE

STAAR Surgical Company, a Delaware corporation, (the “Company”), pursuant to its Amended and Restated Omnibus Equity Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the individual listed below (“Participant”), in consideration of the mutual agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, an option to purchase the number of shares of the Company’s Common Stock (“Stock”), set forth below (the “Option”). This Option is subject to all of the terms and conditions set forth herein, as well as in the Plan and the Stock Option Agreement attached hereto as Exhibit A(the “Agreement”), each of which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Agreement. A Prospectus regarding the Stock is available at https://staarus.sharepoint.com/sites/STAARNET.

For purposes of this Grant Notice and the Agreement, each of the terms “Cause,” “Disability” and “Good Reason” shall have the meaning ascribed to such term in that certain Amended and Restated Severance Agreement by and between the Company and the Participant, dated as of August 4, 2026, as may be amended from time to time.

| |

STAAR SURGICAL COMPANY

AMENDED AND RESTATED OMNIBUS EQUITY INCENTIVE PLAN

STOCK OPTION GRANT NOTICE

STAAR Surgical Company, a Delaware corporation, (the “Company”), pursuant to its Amended and Restated Omnibus Equity Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the individual listed below (“Participant”), in consideration of the mutual agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, an option to purchase the number of shares of the Company’s Common Stock (“Stock”), set forth below (the “Option”). This Option is subject to all of the terms and conditions set forth herein, as well as in the Plan and the Stock Option Agreement attached hereto as Exhibit A(the “Agreement”), each of which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Agreement. A Prospectus regarding the Stock is available at https://staarus.sharepoint.com/sites/STAARNET.

For purposes of this Grant Notice and the Agreement, each of the terms “Cause,” “Disability” and “Good Reason” shall have the meaning ascribed to such term in that certain Amended and Restated Severance Agreement by and between the Company and the Participant, dated as of [DATE], 2026, as may be amended from time to time.

| |

STAAR SURGICAL COMPANY

AMENDED AND RESTATED OMNIBUS EQUITY INCENTIVE PLAN

STOCK OPTION GRANT NOTICE

STAAR Surgical Company, a Delaware corporation, (the “Company”), pursuant to its Amended and Restated Omnibus Equity Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the individual listed below (“Participant”), in consideration of the mutual agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, an option to purchase the number of shares of the Company’s Common Stock (“Stock”), set forth below (the “Option”). This Option is subject to all of the terms and conditions set forth herein, as well as in the Plan and the Stock Option Agreement attached hereto as Exhibit A(the “Agreement”), each of which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Agreement. A Prospectus regarding the Stock is available at https://staarus.sharepoint.com/sites/STAARNET.

For purposes of this Grant Notice and the Agreement, each of the terms “Cause,” “Disability” and “Good Reason” shall have the meaning ascribed to such term in that certain Amended and Restated Severance Agreement by and between the Company and the Participant, dated as of August 4, 2026, as may be amended from time to time.

| |

GEORGIA COMMERCIAL LEASE AGREEMENT

** **

I. The Parties. This Commercial Lease Agreement (“Agreement”) made this January 2nd, 2025 by and between:

Landlord. ONIUM CAPITAL, LLC, of 2680 Dravton Hall Drive, Buford, GA 30519 State of Georgia, (“Landlord”)

AND

Tenant. Secured Transportation Services, LLC , of 90 West Moreno Street Buford GA 30518. State of Georgia , (“Tenant”). Collectively, the Landlord and Tenant shall be referred to herein as the “Parties”.

The Parties agree as follows:

ll. DESCRIPTION OF LEASED PREMISES. The Landlord agrees to lease to the Tenant the following described ~2200 square feet (SF) of office and ~2500 square feet of warehouse located at 575 Smith Cemetery Road, Suite B, Winder GA 30680 State of Georgia.

Additional Description: including parking and lawn space

Hereinafter known as the “Premises”.

Ill. USE OF LEASED PREMISES. The Landlord is leasing the Premises to the Tenant and the Tenant is hereby agreeing to lease the Premises for the following use and purpose: engineering offices

Any change in use or purpose the Premises other than as described above shall be upon prior written consent of Landlord only.

IV. TERM OF LEASE. The term of this Lease shall be for a period of 1 year(s) *0 *month(s) commencing on the 1 day of January , 2028. (“Initial Term”)

…

AMENDMENT TO INDEPENDENT DIRECTOR AGREEMENT

** **

This AMENDMENT TO INDEPENDENT DIRECTOR AGREEMENT (“Amendment”) is entered into as of August 10, 2026 (the “Amendment Date”), by and between Nano Nuclear Energy Inc. (the “Company”) and Diane Hare, an individual (the “Independent Director”).

WHEREAS, the Company and the Independent Director entered into that certain Independent Director Agreement, dated April 28, 2023 (the “Agreement”);

WHEREAS, pursuant to its terms, the Agreement expired on April 27, 2025;

WHEREAS, following the expiration of the Agreement, the Company and the Independent Director continued their relationship pursuant to the terms of the Agreement through their course of conduct without interruption, and now desire to memorialize such continuing relationship by extending the term of the Agreement and amending certain provisions of the Agreement as set forth herein; and

WHEREAS, the parties wish for the Agreement, as amended by this Amendment, to continue in full force and effect from and after April 27, 2025.

NOW THEREFORE, in consideration of the mutual premises, covenants and agreements hereinafter set forth, and for other good and valuable consideration, the receipt, and legal adequacy of which is hereby acknowledged, the Company and the Independent Director, intending to be legally bound, hereby agree to amend the Agreement as follows:

…

AMENDMENT TO INDEPENDENT DIRECTOR AGREEMENT

** **

This AMENDMENT TO INDEPENDENT DIRECTOR AGREEMENT (“Amendment”) is entered into as of August 10, 2026 (the “Amendment Date”), by and between Nano Nuclear Energy Inc. (the “Company”) and Kenny Yu, an individual (the “Independent Director”).

WHEREAS, the Company and the Independent Director entered into that certain Independent Director Agreement, dated May 8, 2023 (the “Agreement”);

WHEREAS, pursuant to its terms, the Agreement expired on May 7, 2025;

WHEREAS, following the expiration of the Agreement, the Company and the Independent Director continued their relationship pursuant to the terms of the Agreement through their course of conduct without interruption, and now desire to memorialize such continuing relationship by extending the term of the Agreement and amending certain provisions of the Agreement as set forth herein; and

WHEREAS, the parties wish for the Agreement, as amended by this Amendment, to continue in full force and effect from and after May 7, 2025.

NOW THEREFORE, in consideration of the mutual premises, covenants and agreements hereinafter set forth, and for other good and valuable consideration, the receipt, and legal adequacy of which is hereby acknowledged, the Company and the Independent Director, intending to be legally bound, hereby agree to amend the Agreement as follows:

…

AMENDMENT TO CONSULTING AGREEMENT

** **

This AMENDMENT TO CONSULTING AGREEMENT (“Amendment”) is entered into as of August 10, 2026 (the “Amendment Date”), by and between Nano Nuclear Energy Inc. (the “Company”) and Tsun Yee Law, an individual (the “Independent Director” or “Consultant”).

WHEREAS, the Company and the Independent Director entered into that certain Consulting Agreement, dated February 8, 2022 (the “Agreement”);

WHEREAS, pursuant to its terms, the Agreement expired on February 7, 2025;

WHEREAS, following the expiration of the Agreement, the Company and the Independent Director continued their relationship pursuant to the terms of the Agreement through their course of conduct without interruption, and now desire to memorialize such continuing relationship by extending the term of the Agreement and amending certain provisions of the Agreement as set forth herein; and

WHEREAS, the parties wish for the Agreement, as amended by this Amendment, to continue in full force and effect from and after February 7, 2025.

NOW THEREFORE, in consideration of the mutual premises, covenants and agreements hereinafter set forth, and for other good and valuable consideration, the receipt, and legal adequacy of which is hereby acknowledged, the Company and the Independent Director, intending to be legally bound, hereby agree to amend the Agreement as follows:

…

THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

AMENDED AND RESTATED PROMISSORY NOTE

August 11, 2026

Principal Amount: $750,000.00

Blue Water Acquisition Corp. III, a Cayman Islands exempted company and blank check company (the “Maker”), promises to pay to the order of Yorkville BW Acquisition Sponsor, LLC, a Florida limited liability company, or its registered assigns or successors in interest (the “Payee”), or order, the principal sum of Seven Hundred Fifty Thousand Dollars ($750,000.00) in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

…

Termination Agreement

This Termination Agreement (“Agreement”) is entered into as of August 11, 2026 (the “Effective Date”) by and between:

EVEREST MEDICINES II LIMITED, a company incorporated under the laws of the Cayman Islands (“Everest”), with its registered office address at Vistra (Cayman) Limited, P.O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205, Cayman Islands;

and

SPERO THERAPEUTICS, INC., a corporation organized under the laws of Delaware (“Spero”), with its principal place of business at 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts, 02139.

(Everest and Spero are each referred to herein as a “Party” and collectively as the “Parties”).

WHEREAS:

(A) Everest, Spero and its Affiliates entered into that certain License Agreement dated January 1, 2019 (the “Original License Agreement”), and the Amended and Restated License Agreement dated January 15, 2021 (the “A&R License Agreement”, collectively with the Original License Agreement, the “License Agreement”), the Material Transfer Agreement dated March 28, 2019 (the “MTA”) and the Pharmacovigilance Agreement dated June 30th, 2021, as amended by Amendment 1 to Pharmacovigilance Agreement dated as of March 11, 2022 (the “Pharmacovigilance Agreement”, collectively with the License Agreement and the MTA, the “Collaboration Agreements”), for the development and commercialization of the licensed compound SPR206 (the “Licensed Product”) within the Licensed Territory

…

EXECUTIVE EMPLOYMENT AGREEMENT

This Executive Employment Agreement (this “Agreement”) is effective as of this 3rd day of August 2026 (the “Effective Date”) by and between Spero Therapeutics, Inc., a Delaware corporation (“Company”), and Debra Jeske Zack, MD, PhD (“Executive”).

WHEREAS, Executive and Company desire to set forth the terms and conditions for the employment of the Executive by the Company to assure the harmonious performance of the affairs of Company as well as to enter into a Proprietary Information and Inventions Assignment Agreement (the “Restrictive Covenant Agreement”).

NOW, THEREFORE, in consideration of the mutual promises, terms, provisions, and conditions contained herein, Company and Executive hereby agree as follows:

1.

Roles and Duties. Subject to the terms and conditions of this Agreement, Company shall employ Executive as its Chief Medical Officer (“CMO”), reporting to Company’s Chief Executive Officer (“CEO”). The Executive shall have such duties and responsibilities as are reasonably determined by the CEO and are consistent with the duties customarily performed by a CMO of a similarly situated company in the United States. Executive accepts such employment upon the terms and conditions set forth herein, and agrees to perform such duties and discharge such responsibilities to the best of Executive’s ability. During Executive’s employment, Executive shall devote all of Executive’s business time and energies to the business and affairs of Company. Notwithstanding the foregoing, nothing herein shall preclude Executive from (i) performing

…